Popular Weight Loss Drugs No Longer in Shortage; FDA to Limit Cheaper Alternatives

The removal of the FDA-approved weight loss drugs from FDA’s shortage list will limit compounding pharmacies’ production of cheaper versions.

Mounjaro, an injectable medicine used to treat type 2 diabetes, is seen in an undated file photo. PA

The FDA has officially removed popular weight loss drugs, including Lilly’s Mounjaro and Zepbound, from its drug shortage list, signaling the end of a nearly two-year period of scarcity that allowed compounding pharmacies to produce more affordable versions of these medications.

“FDA confirmed with the drug’s manufacturer that their stated product availability and manufacturing capacity can meet the present and projected national demand,” the agency said.